Balchem Corp. 10-Q Summary: Period Ended September 30, 2006
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation, an accelerated filer incorporated in Maryland. The report covers the three and nine-month periods ended September 30, 2006. Balchem develops, manufactures, and distributes specialty performance ingredients for food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The company operates through three segments: Specialty Products, Encapsulated/Nutritional Products, and BCP Ingredients.
Key Financial Metrics (Nine Months Ended Sept 30, 2006)
| Metric | 2006 (9 Months) | 2005 (9 Months) |
|---|---|---|
| Net Sales | $74,819 | $59,969 |
| Gross Profit | $25,695 | $21,943 |
| Gross Margin % | 34.3% | 36.6% |
| Operating Income | $14,320 | $13,041 |
| Net Earnings | $9,064 | $8,322 |
| Diluted EPS | $0.75 | $0.69 |
| Cash from Operations | $14,313 | $9,827 |
| Cash & Equivalents (End) | $2,660 | $10,723 |
| Total Debt | $0 | $0 |
Note: Debt figures reflect the repayment of a $10,000 term loan used for the CMC acquisition. A $3,000 revolving credit facility remains available but undrawn.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24.8% year-over-year, driven by volume growth and acquisitions. The Encapsulated/Nutritional segment grew 32.6%, and BCP Ingredients grew 37.1%.
- Acquisitions: Significant growth was attributed to the February 2006 acquisition of Chelated Minerals Corporation (CMC) and the June 2005 acquisition of assets from Loders Croklaan USA. A new choline chloride facility in St. Gabriel, Louisiana, was acquired in August 2006.
- Margin Compression: Gross margin percentage declined from 36.6% to 34.3% due to higher raw material and fuel costs and product mix changes.
- Operating Expenses: Increased 27.8% to $11.375 million, primarily due to payroll for new hires, amortization from acquisitions, and the adoption of SFAS 123R (stock-based compensation).
- Liquidity: Cash and cash equivalents decreased by $10.3 million to $2.66 million, largely due to $22.8 million in cash used for acquisitions and asset purchases.
Guidance, Outlook, and Risks
- Outlook: Management expects operations to generate sufficient cash flow for working capital and capital investments. Capital expenditures for 2006 are projected at approximately $2.5 million.
- Accounting Changes: The company adopted SFAS 123R effective January 1, 2006, resulting in $786,000 of stock-based compensation expense for the nine months ended September 30, 2006. Estimated total expense for 2006 is $1.048 million.
- License Agreement: A license agreement with Project Management and Development Co., Ltd. (PMD) for choline chloride technology in Saudi Arabia is ongoing, with revenue recognized based on the percentage of completion method.
- Risks: The filing references risk factors from the 2005 10-K, including exposure to raw material costs and the integration of acquired businesses. There are no material changes to risk factors noted in this filing.
Investor Verification Checklist
- Acquisition Integration: Verify the operational status and revenue contribution of the CMC and St. Gabriel, Louisiana facilities.
- Debt Status: Confirm the full repayment of the $10 million term loan and the terms of the $3 million revolving credit facility expiring in February 2007.
- Cost Pressures: Monitor the impact of rising raw material and fuel costs on future gross margins.
- Stock Compensation: Review the impact of SFAS 123R on future earnings, noting $1.625 million in unrecognized compensation costs remaining.
- Liquidity Position: Assess the company's ability to fund future acquisitions given the significant reduction in cash reserves from $13.0 million to $2.7 million.